| Catalog No. | YP598016 |
|---|
| Species reactivity | General |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | Fab-G1-kappa |
|---|
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Dabigatran Etexilate Mesylate |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
211915-06-9 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | aDabi-Fab, anti-dabigatran, antidotefordabigatran, CAS: 1362509-93-0 |
|---|
| Background | Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis.
• Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial., PMID:33290737
• Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism., PMID:35699915
• The polymorph landscape of dabigatran etexilate mesylate: Taking the challenge to bring a metastable polymorph to market., PMID:37044200
• Dose tailoring of dabigatran etexilate: obvious or excessive?, PMID:25994994
• A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects., PMID:31652461
• Idarucizumab for Dabigatran Reversal - Full Cohort Analysis., PMID:28693366
• Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation., PMID:28185082
• Direct oral anticoagulants: evidence and unresolved issues., PMID:33248499
• Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta., PMID:24807346
• The discovery of dabigatran etexilate for the treatment of venous thrombosis., PMID:27159158
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
